Form 4: Crinetics Pharmaceuticals Executive Acquires Shares and Options

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, acquired shares and options in the company on March 4, 2024.

Summary

• Dana Pizzuti, Chief Medical and Development Officer at Crinetics Pharmaceuticals, reported changes in beneficial ownership on March 6, 2024.
• On March 4, 2024, Pizzuti acquired 23,000 shares of common stock at $0.00 and disposed of 28,911 shares.
• Additionally, Pizzuti acquired options to purchase 87,000 shares of common stock at an exercise price of $43.51, expiring on March 3, 2034.
• These options vest in 48 equal monthly installments starting March 4, 2024.
• Following these transactions, Pizzuti directly owns 87,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of executive stock transactions. The acquisition of shares and options could be seen as a mildly positive sign, but it's not a strong indicator of future performance.

Positives

• The acquisition of shares and options by a key executive could be interpreted as a positive signal about the company's future prospects.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules for the restricted stock units and stock options suggest a multi-year commitment from the executive.

Industry Context

Executive stock ownership is a common practice in the pharmaceutical industry to align management's interests with those of shareholders. These transactions are routinely monitored by investors for insights into executive sentiment.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, often used by companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals.
• Vesting schedules, such as the four-year monthly vesting for the options, are typical to incentivize long-term performance.
• The size of the grant (87,000 options) would need to be compared against grants to executives with similar roles at comparable companies to assess its relative magnitude.

Stakeholder Impact

• Shareholders may view the executive's stock acquisition as a positive sign of confidence in the company's future.
• Employees may see this as a sign of stability and alignment of interests between management and the company's success.

Key Dates